-
St. Jude finds NLRP12 as a new drug target for infection, inflammation and hemolytic diseases
06/01/2023
NLRP12 bridges hemolysis, inflammation and multi-organ damage. Learn how this ‘on’ switch for innate immune cell death could be a drug target to prevent pathology.
-
Genetic change increased bird flu severity during U.S. spread
05/30/2023
Find how H5N1 avian influenza viruses increased disease-causing abilities & gained the capability to enter mammalian brains as they spread west across North America.
-
SWI/SNF complexes “bookmark” cell identity during division
05/24/2023
Read about how Scientists at St. Jude determined how the SWI/SNF chromatin remodeling complex helps cancer cells remember how to be cancerous after division.
-
Epigenetic landscape modulates pioneer transcription factor binding
05/24/2023
St. Jude scientists are studying how pioneer transcription factors access tightly wound DNA. Learn about how their findings may impact therapeutic development.
-
Capturing transporter structure paves the way for drug development
05/23/2023
Learn how St. Jude scientists captured six new structures of the Spns2 transporter, providing insights to aid therapeutic design for cancer and other diseases.
-
St. Jude scientist M. Madan Babu elected to the Royal Society of London
05/10/2023
Director of the St. Jude Center of Excellence for Data-Driven Discovery named a fellow of the 360-year-old British scientific organization.
-
St. Jude tool gets more out of multi-omics data
05/04/2023
NetBID2 finds hidden drivers by extracting more from multi-omics data. Learn how the computational tool can find druggable targets in cancer and other diseases.
-
Study shines light on impact of environment on neurocognitive outcomes
04/28/2023
Find how the neighborhood economic hardship index predicts baseline and long-term outcomes in pediatric brain tumor patients treated with radiation therapy.
-
Clinical trial improves neurocognitive outcomes for childhood craniopharyngioma
04/18/2023
Proton therapy for craniopharyngioma had better neurocognitive than & similar survival outcomes as historical photon therapy. Read the phase 2 clinical trial.
-
Prime editing shows proof of concept for treating sickle cell disease
04/17/2023
Genomic prime editing, a new DNA-changing technology, fixed sickle cell disease mutations in patient cells. Learn how it could lead to cure for genetic anemias.
Explore more research news
More Research News
-
2022 Scientific Report
The Scientific Report, Translating Science into Survival, describes key breakthroughs made by St. Jude investigators.
Clinical Trials Alerts
Our e-newsletter for clinicians offers updates on St. Jude open clinical trials and research news.
Follow Us on Social Media
Connect with @stjuderesearch to keep up with our latest science and medical news. More about St. Jude social media.
Peer-Reviewed Publications
Browse all scientific publications by St. Jude investigators.